A Radical Alternative to Animal Testing
A San Francisco biotech startup is proposing what may be the most provocative solution yet to one of medicine’s longest-standing ethical debates: what if laboratory animals were replaced entirely by living, brain-free human organ systems grown from human cells?
R3 Bio, backed by billionaire investors and quietly gaining attention in pharmaceutical and longevity circles, is developing structures it calls “bodyoids” — complete organ systems engineered without a brain. These entities would contain every major organ except the one responsible for consciousness, sensation, and pain. The result, in theory, is a biologically complete human-like system that can be used for drug testing, disease research, and eventually organ transplantation — without the ethical burden of using a sentient living creature.
The concept is unconventional. The science is still developing. However, the money is serious, and the timing — as the Trump administration moves to phase out animal experimentation across federal agencies — could not be more relevant.
What R3 Bio Is Building and Why
R3 Bio’s name is itself a statement of intent. It references the three R’s of animal research ethics — replacement, reduction, and refinement — a framework developed by British scientists William Russell and Rex Burch in 1959 to promote more humane scientific experimentation. The company’s entire philosophy is built around the first of those three principles: replacement.
Co-founder and CEO Alice Gilman co-founded the company alongside John Schloendorn. Together, they argue that modern drug development is constrained by a fundamental flaw in its methodology. As Gilman has written: “The human body is not a collection of parts; it’s a system. We can’t keep studying diseases in pieces and hoping the results will scale.”
The Problem with Current Testing Models
Existing alternatives to whole-animal testing — such as organs-on-chips or isolated tissue cultures — lack the full complexity of real organs, including their vascular systems and their interactions with other organs. Drugs that behave safely in one isolated tissue may produce dangerous effects when they encounter the full biological system. Consequently, pharmaceutical developers currently rely on whole animals — particularly primates — to generate the systems-level safety data that regulators require before human trials.
R3 Bio argues that its organ sacks could provide that systems-level complexity while also being more scalable, more human-relevant, and free of the ethical objections that attach to the use of living, sentient animals.
Brain-Free by Design: The Ethics Argument
The defining feature of R3 Bio’s bodyoids is not what they contain — it is what they deliberately exclude. Every structure the company engineers omits the brain entirely. Without a brain, these systems cannot develop consciousness, cannot experience sentience, and cannot process pain. That absence, the company argues, removes the central ethical objection to the use of living biological material in scientific research.
Gilman has been careful about how this is framed publicly. She prefers not to use the term “brainless” to describe the organ sacks. “It’s not missing anything,” she told Wired, “because we design it to only have the things we want.” That framing positions the absence of a brain not as a deficiency but as an intentional engineering choice — a feature, not a limitation.
Why This Matters for the Regulatory Environment
The Trump administration has been actively moving to reduce the use of animal experimentation across the federal government, creating both urgency and opportunity for companies working on alternatives. Within that context, R3 Bio’s approach offers a potential solution that aligns with regulatory priorities while also addressing longstanding concerns raised by animal welfare advocates. The convergence of those pressures gives the company’s development timeline an unusual degree of political tailwind.
The Roadmap from Mice to Humans
R3 Bio’s development path follows a staged progression designed to build biological credibility and regulatory confidence at each step before moving to the next.
The first stage involves mouse organ sacks. Gilman and Schloendorn have stated that the technology to create headless mouse organ systems already exists in principle, though they deny having created them yet in practice. Mouse models would allow the company to validate the core concept — that a functioning, integrated organ system can be grown and maintained without a brain — before advancing to more complex subjects.
Primates Come Next
The second stage targets monkeys. New drugs are routinely tested in nonhuman primates before entering human clinical trials. Primates have been especially critical in vaccine development and infectious disease research, as demonstrated during the COVID-19 pandemic. If R3 Bio can demonstrate that monkey organ sacks produce equivalent or superior safety data to whole-animal primate testing, it would represent a breakthrough with immediate commercial and regulatory applications.
The company estimates that approximately 60,000 nonhuman primates were used in US research facilities in 2024 alone. Replacing even a fraction of those with organ sacks would constitute a significant reduction in animal use — and a significant market opportunity.
Human Bodyoids Are the End Goal
The third and most ambitious stage involves creating organ systems from human cells. These human bodyoids would offer the most accurate possible model of human biological responses to drugs, toxins, and disease — more predictive than animal models and more comprehensive than any existing in vitro alternative.
How These Organ Systems Would Actually Be Made
Gilman and Schloendorn have declined to disclose specific technical methods for producing the monkey and human versions of their organ systems. Nevertheless, the general approach is plausible enough that independent scientists take it seriously.
Paul Knoepfler, a stem cell biologist at the University of California Davis, has explained the theoretical pathway publicly. Organ sacks could potentially be grown from induced pluripotent stem cells — adult skin cells that are reprogrammed back to an embryonic-like state. These cells carry the potential to develop into any tissue or organ in the body. Through targeted gene editing, scientists could disable the specific genetic pathways required for brain development. The resulting embryo could then be cultivated until it organises into a full system of functional organs — without the neural structures that would make it sentient.
This approach builds on established stem cell science and gene editing technology. It extends both in a direction that has not yet been fully explored but is widely regarded as technically feasible in principle.
The Primate Crisis Driving Urgency
Part of what makes R3 Bio’s timing significant is an existing and worsening crisis in the supply of research primates. China banned the export of nonhuman primates in 2020, sharply reducing the availability of monkeys for US-based research. Animal rights advocacy has intensified pressure on the remaining primate research infrastructure. One of seven federally funded primate research centres has signalled it may convert to a sanctuary. Additionally, the CDC has already begun scaling back monkey research as part of a broader governmental shift.
The cumulative effect is a research environment where primate access is shrinking precisely as regulatory demand for primate-level safety data remains high. If another pandemic emerged tomorrow, the US would not have adequate primate resources to support the kind of vaccine development that COVID-19 required. That vulnerability makes the search for primate alternatives not just an ethical preference but a matter of national biosecurity.
Organ Transplantation: The Longer Game
Beyond drug testing, R3 Bio’s investors see a second, larger opportunity: organ transplantation. The global shortage of donor organs is one of the most persistent crises in healthcare. Hundreds of thousands of patients wait years for a compatible organ. Many die before one becomes available.
Boyang Wang, CEO of Immortal Dragons — a Singapore-based longevity investment fund that has backed R3 Bio — articulates the vision directly: “We think replacement is probably better than repair when it comes to treating diseases or regulating the aging process in the human body. If we can create a nonsentient, headless bodyoid for a human being, that will be a great source of organs.”
In this framing, organ sacks grown from a patient’s own cells could theoretically provide genetically matched replacement organs on demand — eliminating both the shortage and the rejection risk that makes transplantation so complex. Gilman, who has spoken of her father’s heart transplant as a personal motivation, sees this application as a long-term but serious goal of the programme.
The Ethical Questions That Remain
Even accepting that brain-free organ systems cannot experience consciousness or pain, the broader ethical terrain around this technology is not entirely settled. Several questions remain genuinely open and will require transparent public deliberation.
Oversight and Consent
The use of human cells to create organ systems raises questions about consent — specifically, whose cells would be used, under what terms, and with what rights retained by the donor. Existing frameworks for human tissue donation were not designed with this kind of use in mind.
The Question of Consciousness
Stanford bioethicist Hank Greely has acknowledged that the “yuck factor will be strong” in public responses to this technology. Beyond instinctive discomfort, he and others have raised the more substantive question of whether brain-free systems could, under some circumstances, develop rudimentary forms of awareness or sensitivity that current understanding does not anticipate. The company’s assurances about non-sentience rest on the current state of neuroscience — a field that continues to revise its understanding of what consciousness requires.
Regulatory Validation
For pharmaceutical applications specifically, regulators would need robust frameworks to certify that organ sack data is an acceptable substitute for whole-animal data in safety and efficacy assessments. That validation process does not yet exist and would require significant investment by both the company and regulatory agencies.
What Comes Next for R3 Bio
R3 Bio is not the first company to propose radical alternatives to animal testing, and the path from concept to validated clinical tool is long and uncertain. Nevertheless, the combination of serious financial backing, alignment with federal policy direction, and a genuine gap in the research infrastructure gives this particular startup unusual momentum.
If the company successfully develops reproducible, regulatory-grade mouse organ sacks, it establishes a proof of concept with immediate commercial value. Pharmaceutical developers would gain access to more scalable and human-relevant preclinical testing systems. Regulators would have a concrete model to evaluate. And the broader project — of replacing animal testing with systems that are both more ethical and more accurate — would take a meaningful step forward from theory toward practice.
